JP2015520152A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520152A5
JP2015520152A5 JP2015511772A JP2015511772A JP2015520152A5 JP 2015520152 A5 JP2015520152 A5 JP 2015520152A5 JP 2015511772 A JP2015511772 A JP 2015511772A JP 2015511772 A JP2015511772 A JP 2015511772A JP 2015520152 A5 JP2015520152 A5 JP 2015520152A5
Authority
JP
Japan
Prior art keywords
aryl
membered heterocyclyl
membered
alkyl
carbazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015511772A
Other languages
English (en)
Japanese (ja)
Other versions
JP6377054B2 (ja
JP2015520152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040604 external-priority patent/WO2013170186A1/en
Publication of JP2015520152A publication Critical patent/JP2015520152A/ja
Publication of JP2015520152A5 publication Critical patent/JP2015520152A5/ja
Application granted granted Critical
Publication of JP6377054B2 publication Critical patent/JP6377054B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015511772A 2012-05-11 2013-05-10 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド Expired - Fee Related JP6377054B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645918P 2012-05-11 2012-05-11
US61/645,918 2012-05-11
US201361778176P 2013-03-12 2013-03-12
US61/778,176 2013-03-12
PCT/US2013/040604 WO2013170186A1 (en) 2012-05-11 2013-05-10 Carbazole-containing sulfonamides as cryptochrome modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017140820A Division JP2017200946A (ja) 2012-05-11 2017-07-20 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Publications (3)

Publication Number Publication Date
JP2015520152A JP2015520152A (ja) 2015-07-16
JP2015520152A5 true JP2015520152A5 (enExample) 2017-02-09
JP6377054B2 JP6377054B2 (ja) 2018-08-22

Family

ID=48444649

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015511772A Expired - Fee Related JP6377054B2 (ja) 2012-05-11 2013-05-10 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2017140820A Withdrawn JP2017200946A (ja) 2012-05-11 2017-07-20 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2019015689A Withdrawn JP2019077722A (ja) 2012-05-11 2019-01-31 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2020159390A Withdrawn JP2020203948A (ja) 2012-05-11 2020-09-24 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2022166167A Pending JP2023002659A (ja) 2012-05-11 2022-10-17 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017140820A Withdrawn JP2017200946A (ja) 2012-05-11 2017-07-20 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2019015689A Withdrawn JP2019077722A (ja) 2012-05-11 2019-01-31 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2020159390A Withdrawn JP2020203948A (ja) 2012-05-11 2020-09-24 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
JP2022166167A Pending JP2023002659A (ja) 2012-05-11 2022-10-17 クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Country Status (15)

Country Link
US (3) US9265772B2 (enExample)
EP (1) EP2855458B1 (enExample)
JP (5) JP6377054B2 (enExample)
KR (1) KR102136431B1 (enExample)
CN (2) CN104640856B (enExample)
AR (1) AR092319A1 (enExample)
AU (1) AU2013259294B2 (enExample)
CA (1) CA2873214C (enExample)
IL (1) IL235602A0 (enExample)
MX (1) MX361457B (enExample)
NZ (2) NZ728724A (enExample)
RU (1) RU2654484C1 (enExample)
SG (1) SG11201407402TA (enExample)
TW (2) TWI643845B (enExample)
WO (1) WO2013170186A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ728724A (en) * 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
UA121203C2 (uk) * 2013-12-13 2020-04-27 Аллерган, Інк. Спосіб отримання поліморфної форми стероїдоподібної сполуки
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
KR101542324B1 (ko) * 2014-04-09 2015-08-05 동아대학교 산학협력단 손상된 dna의 회복 속도 비교를 위한 정보 제공 방법
WO2015185487A1 (en) * 2014-06-04 2015-12-10 Roche Diagnostics Gmbh Method and device for separating metabolites or stereoisomers by ion mobility spectrometry
TWI742105B (zh) 2016-07-04 2021-10-11 德商拜耳作物科學公司 苯并磺內醯胺及類似物
CN107941976B (zh) * 2017-09-28 2019-11-19 浙江新化化工股份有限公司 一种2-甲氧基环己胺的含量测定方法
JP7187152B2 (ja) * 2018-01-12 2022-12-12 三星電子株式会社 化合物、有機エレクトロルミネッセンス素子用材料、有機エレクトロルミネッセンス素子用組成物、有機エレクトロルミネッセンス素子、及び化合物の製造方法
CN112996506A (zh) 2018-08-14 2021-06-18 奥斯特克有限公司 吡咯并二吡啶化合物
US20220081433A1 (en) * 2018-09-05 2022-03-17 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
CN109232596B (zh) * 2018-09-05 2020-03-17 大连九信精细化工有限公司 一种二苯并呋喃咔唑的合成方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN114854803A (zh) * 2022-04-21 2022-08-05 山东农业大学 镰刀菌对3,6-二氯咔唑生物降解的方法
CN115974763B (zh) * 2022-12-26 2025-03-11 常州大学 一种咔唑衍生物及其应用
CN116217467A (zh) * 2023-03-09 2023-06-06 烟台皓元生物医药科技有限公司 一种erdrp-0519的中间体及其制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
CA1178414A (en) 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4325952A (en) 1978-04-18 1982-04-20 Aziende Chimiche Riunite Angelini Francesco Method of treating abstinence syndrome with cycloaklyltriazoles
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4276890A (en) 1979-04-11 1981-07-07 Fichera Anthony T Tobacco smoking inhibitor
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US4780401A (en) 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US4786653A (en) 1987-08-24 1988-11-22 Golwyn Daniel H Treatment of neurotransmitter-linked drug abuse
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5081127A (en) 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
DE4004820A1 (de) 1989-08-05 1991-04-25 Bayer Ag Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5750015A (en) 1990-02-28 1998-05-12 Soane Biosciences Method and device for moving molecules by the application of a plurality of electrical fields
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5085992A (en) 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995018799A1 (en) 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JPH10507765A (ja) 1994-10-27 1998-07-28 メルク フロスト カナダ インコーポレーテツド シクロオキシゲナーゼ−2阻害剤として有用なスチルベン誘導体
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5801155A (en) 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
WO2000059885A1 (en) * 1999-04-01 2000-10-12 Asahi Kasei Kabushiki Kaisha Method for the preparation of tricyclic amino alcohol derivatives through azides
US6475744B1 (en) * 1999-07-22 2002-11-05 The General Hospital Corporation Methods for identifying compounds which modulate circadian rhythm
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
EP1236173A2 (en) 1999-10-27 2002-09-04 Biowulf Technologies, LLC Methods and devices for identifying patterns in biological systems
KR20020069215A (ko) * 1999-12-16 2002-08-29 아사히 가세이 가부시키가이샤 신규한 치환기를 갖는 3환성 화합물
KR101054732B1 (ko) 2000-07-18 2011-08-05 더 유나이티드 스테이츠 오브 아메리카 애즈 리프리젠티드 바이 더 세크레터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 생물학적 데이터의 숨겨진 패턴에 근거한 생물학적 상태의 식별 방법
CA2429633A1 (en) 2000-11-16 2002-05-30 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
WO2003105759A2 (en) 2002-06-12 2003-12-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pharmacologic inhibition of myc function
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
WO2004088309A2 (en) 2003-03-28 2004-10-14 Cantata Laboratories, Inc. Methods for diagnosing urinary tract and prostatic disorders
US20090163454A1 (en) 2003-05-02 2009-06-25 Duramed Pharmaceuticals, Inc. Methods of Step-Down Hormone Treatment
US7280776B2 (en) 2003-08-25 2007-10-09 Lexmark International, Inc. Method and apparatus to control waste toner collection in an image forming apparatus
PL1732892T3 (pl) * 2004-03-26 2009-03-31 Hoffmann La Roche Tetrahydrokarbazole i pochodne
DE602005017162D1 (de) * 2004-08-19 2009-11-26 Aventis Pharma Inc 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
ES2882684T3 (es) 2006-04-07 2021-12-02 Vertex Pharma Preparación de moduladores de transportadores del casete de unión a ATP
CL2007003591A1 (es) 2006-12-12 2008-02-29 Wyeth Corp Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 11ベータ−hsd1活性化合物
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
WO2010081115A1 (en) 2009-01-09 2010-07-15 University Of Texas Southwestern Medical Center Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
US20130116445A1 (en) 2010-07-12 2013-05-09 Colorado State University Research Foundation Triazolium carbene catalysts and processes for asymmetric carbon-carbon bond formation
NZ728724A (en) * 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
WO2014031125A1 (en) * 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2014039515A2 (en) 2012-09-04 2014-03-13 University Of Massachusetts Antifungal agents and uses thereof
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
US9353078B2 (en) 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類

Similar Documents

Publication Publication Date Title
JP2015520152A5 (enExample)
JP2017510611A5 (enExample)
JP6790183B2 (ja) Ask1阻害剤の固体形態
US11161831B2 (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
Rammohan et al. A gist of gastrointestinal stromal tumors: A review
RU2016143304A (ru) Содержащие карбазол амиды, карбаматы и карбамиды в качестве модуляторов криптохромов
RU2602185C2 (ru) Биомаркеры для терапии на основе ингибитора hedgehog
AU2019299444A1 (en) Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist
Algooneh et al. Non-alcoholic fatty liver disease resolution following sleeve gastrectomy
CN102239164A (zh) 2h-色烯化合物及其衍生物
Soverini et al. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias
JP2013541339A5 (enExample)
JP2018530608A5 (enExample)
Wettersten et al. Potential biofluid markers and treatment targets for renal cell carcinoma
JP2012502962A5 (enExample)
JP2024513560A (ja) 加齢に関連する筋肉状態を処置するためのアペリン受容体モジュレーター
TW202535399A (zh) 用於治療實性瘤之方法與包含 krasg12c 抑制劑及 vegf 抑制劑之組成物
JP6837632B2 (ja) 体液試料の単位量当たりのセルフリーdna量を健康状態の評価のための指標とする方法
Miwa et al. Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis
Leng et al. Blocking TRAIL-DR5 signaling with soluble DR5 alleviates acute kidney injury in a severely burned mouse model
Karcz et al. [OP. 4B. 06] FREQUENCY OF PRIMARY ALDOSTERONISM IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA–OSA-PA STUDY
Deliu et al. Prognostic implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in head and neck squamous cell carcinoma (HNSCC)
CN103272221B (zh) Wsb-1蛋白在制备治疗骨肉瘤药物中的应用
JP2018535997A5 (enExample)
Davies Finding the right balance of BRAF inhibition in melanoma